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3-carboxylate; DMCM) and electric foot-shock on rat conflict
behavior were characterized and compared. Rats were trained
to lever press under a multiple fixed-ratio schedule (FR 20) of
food reinforcement in which responses during the first compo
nent were not punished, and the first response of each FR during
the second component produced electric shock of an intensity
sufficientto suppressrespondingby 10% to 15%. Intracerebro
ventricular injection of CRF (0.1â€”5.6@g)caused a dose-depend
ent decrease in the rate of responding in both components of
the schedule.However,CRF was more potent in decreasing
rates of punishedresponding(proconflicteffect). DMCM(10â€”
100 @g;i.c.v.) also decreased rates of punished and nonpunished
responding and was more potent during the punishment corn
ponent. The suppression of punished and nonpunished respond
ing by CRF and DMCM was mimicked by increasing the shock
intensity (L@= 0.1 to 0.6 mA) during the punishment component.
To determine whether CRF, DMCM and electric shock shared
common mechanismsfor these effects, rats were pretreated
with i.c.v. injectionsof eithera CRFantagonist(a helicalCRF@..
41 , 50 ,@g), a benzodiazepine agonist (chlordiazepoxide, 1 0 @g)
or a benzodiazepineantagonist(flumazenil,10 @g)before the
administrationof equieffectivedoses of CRF or DMCM or an
increase in shock intensity. Chlordiazepoxide attenuated the
effects of all three stimuli. Flumazenil antagonized DMCM and
CRF, but not shock, implicating a pharmacologic interaction
between CRF and benzodiazepinesystems. In contrast, a helical
CRFB..@IlantagonizedCRF andshock,butnotDMCM, suggesting
that the effects of shock, but not of DMCM, may be due to
endogeneous CRF release. Together, the present results mdi
cate that the proconflicteffectsof CRF, DMCM andelectricfoot
shock share some common mechanisms and that the effects
produced by CRF may require the release of an endogenous
benzodiazepine inverse agonist.
The 41-amino acid neuropeptide, corticotropin-releasing fac
tor, is the prime physiologic regulator of the hypothalamic
pituitary-adrenal axis during stress (Rivier et at., 1982; Vale et
at., 1981, 1983). Apart from its neurohormonal role in the
pituitary, CRF is also thought to serve as a neurotransmitter
or neuromodulator in extrahypophyseal regions to mediate
autonomic and behavioral components of stress responses(see
Vale et at., 1983; Valentino, 1988; Dunn and Berridge, 1990 for
reviews). Many of the behavioral effects produced by central
administration of CRF are consistent with a role of CRF in
anxiety (Dunn and Berridge, 1990 for review). In support of
this, abnormalities in CRF function have been associatedwith
Received for publication October 28, 1991.
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Substantial clinical and experimental evidence indicates that
brain benzodiazepine/GABA-ergic systems are also intimately
involved in the physiologic control of stress/anxiety responses.
For example, it is well documented that anxiolytic benzodiaze
pine receptoragonistsgenerallyblock or attenuate the physi
ologic, neuroendocrine and behavioral manifestations of stress
(Hommer et at., 1987;File et at., 1988;De Boer et aL, in press).
On the other hand, administration of benzodiazepine receptor
inverse agonists such as the @-carbolines,FG 7142, @3-CCEand
DMCM, has been shown to evoke a profound stress/anxiety
like profile of electrophysiologic, neurochemical, endocrine/
autonomic and behavioral responses qualitatively similar to
those elicited by i.c.v. CRF injection (for reviews see:Hommer
et at., 1987; File and Baldwin, 1987; File et at., 1988; Theibot et
at., 1988; De Boer et aL, in press). Further support for the role
of brain benzodiazepine/GABA-ergic systems in stress and
335
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anxiety comes from neurochemical studies showing rapid,
stress-induced modifications of the number and biophysical
properties of benzodiazepine/GABA-ergic receptors in discrete
brain regions (Havoundjian et at., 1987).Finally, clinical studies
have shown that certain stress/anxiety-related disorders are
associated with dysfunctions in the benzodiazepine/GABA
ergic receptor system (Nutt et at., 1990;Roy-Byrne et at., 1990).
The fact that brain CRF and benzodiazepine/GABA-ergic
systems are both implicated in the (patho)physiologic expres
sion of stress/anxiety responses suggests a possible functional
interaction betweenthe two. Indeed,it hasbeenshownthat
anxiolytic benzodiazepine receptor agonists can reverse or an
tagonize several CRF-mediated behavioral effects that are
thought to be related to anxiety, e.g., locomotor activation in
an open field (Lee et at., 1987); decreasesin social interaction
(Dunn and File, 1987); enhancement of acoustic startle (Swer
diow et at., 1986); increased defensive withdrawal (Yang et aL,
1990); and potentiation of punishment (proconflict effect)
(Britton et aL, 1985, 1988; Zhang and Barrett, 1990). Accord
ingly, the anxiogenic benzodiazepine inverse agonist FG 7142;
enhances the proconflict action of CRF (Britton et al., 1988).
A relationship between benzodiazepine and CRF neuronal sys
tems is also supported at the neurochemical leveL Thus, the
anxiolytic triazolobenzodiazepine alprazolam exerts effects on
CRF levels in locus ceruleus and hypothalamus/median emi
nence regions opposite to those observedafter stress (Owens et
at., 1989, 1991). Additionally, in vitro studies showed that
alprazolam and diazepam inhibited serotonin-induced CRF
release from rat hypothalamic organ cultures, whereas the
benzodiazepine inverse agonist fl-carboline-3-carboxylic acid
methylester stimulated CRF secretion in this preparation (Cal
ogero et at., 1988; Kalogeras et at., 1990). Together, these
findings suggestthat the agonist (anxiolytic) and inverse ago
nist (anxiogenic) actions of benzodiazepine receptor ligands
involve attenuation or enhancement of CRF neurohormonal/
neurotransmitter function, respectively.
An alternativeexplanationfor the complexCRF/benzodiaze
pine interactions is that the effects of CRF may be mediated
through a direct or indirect modulation of benzodiazepine/
GABA-receptor function. Consistent with this model, the spe
cific benzodiazepine receptor antagonist, flu.mazenil, has been
shown to reverse the proconflict effects of CRF (Britton et ci,
1988), indicating that either CRF itself, or an endogenous
inverse agonist ligand released by CRF, interacts with the
benzodiazepine receptor. In contrast, however, File and col
leagues (1988) were not able to find a reversal by flumazenil of
the CRF effects in the plus-maze or social interaction tests.
Hence, this model of CRF/benzodiazepine receptor interaction
is not clearly resolved yet.
The presentstudywas designedto characterizethe interac
tion between CRF and benzodiazepine systems in behaviors
controlled by aversive stimuli and to determine whether: 1) the
effects ofbenzodiazepine receptor inverse agonists are mediated
via endogenousCRF release;2) the effects of CRY are mediated
through an interaction with benzodiazepine systems;and 3) the
effects of electric shock are mediated through endogenous CRF
and/or benzodiazepine systems. To test these hypotheses the
Geller-Seifter conflict procedure (Geller and Seifter, 1960) was
used. Previous studies using this procedure to investigate effects
of CRF and benzodiazepine inverse agonists failed to show a
selective proconflict effect of these compounds, i.e., nonpun
ished and punished responding were equally suppressed(Prado
de Carvalho et at., 1983; Quintero et at., 1985; Britton et ci,
1985, 1988;Koob et ci, 1986; Barrett et ci, 1989). The failure
to find a selective proconflict effect may have been due to the
shock intensity used, because shock intensity is a critical de
terminant for revealing proconflict effects of drugs acting on
the benzodiazepine/GABAA-receptorcomplex (Shekhar et ci,
1989;Giusti et at., 1991;Takada et at., 1992). Therefore, in the
present study, a punishment procedure was used with a sub
threshold intensity of shock that only minimally suppressed
responding so that it would be possible to observe an increase
in the effectivenessofelectric shock after drug treatment. Using
this procedure, the proconflict effects of CRF and the benzo
diazepine inverse agonist, DMCM, were compared with those
produced by increasing intensities of electric foot-shock, and
the sensitivity of each stimulus to antagonism by the benzodi
azepine agonist, chlordiazepoxide, the benzodiazepine antago
nist, flumazenil, and the CRF antagonist, a helical CRF@1,
wasassessed.
Methods
Animals. Twentyadult maleSprague-Dawleyrats (TaconicFarms,
Inc., Germantown, NJ) weighing 276 to 300 g upon arrival in the
laboratory were used as subjects in these studies. Animals were housed
individually in polycarbonatecageswith woodshavingsandplacedin
a roomwith constant temperature(22 Â±0.5Â°C)and 12 hr light-12 hr
dark lighting conditions (lights on from 7:00 A.M.to 7:00 P.M.).Tap
water was freely available except during the experimental sessions.
Ratswerereducedto approximately85%of theirunrestricted-feeding
bodyweights(347Â±8 g)andthenmaintainedon 12to 15gof standard
laboratorychow(Purina,5001)per day in additionto the foodpellets
obtained during the experimental sessions.
Apparatus.Threetwo-leveroperantconditioningchambers(BBS!
LyE, Laurel,MD), equippedwith a houselight,three responselights
above the levers (white, green and red) and a grid floor, were used. A
food-pellet dispenser delivered 45-mg pellets (Bioeerv, Inc., French
town, NJ) to a tray placed between the levers. The bars of the grid
floor were connected to a constant-current shock generator/scrambler
(BBS/LyE). The operant chambers were enclosed individually within
sound-attenuatingboxesequippedwith aventilationfan,andall boxes
wereplacedin a sound-attenuatingroomadjacentto a roomcontaining
the programming equipment. Experimental control and data collection
were providedby a microcomputeroperatingMED-PC softwareand
controlling a solid-state interface (MED Associates, East Fairfield,
VT).
Surgery and Infusions. To enablecentraladministrationof pep
tide, drug and vehicle solutions, rats were prepared with stainless-steel
cannula guides aimed at the lateral ventricle. Rats were anesthetized
with a mixtureof halothane-in-air(1-2%)administeredthroughanose
cone, then positioned in a Narishige stereotaxic instrument with non
injurious ear bars. The headwas oriented at a 15Â°angle to the horizontal
plane (nose down).Body temperaturewas maintainedat 37'C with a
small temperature-controlled heating pad The skull was exposed with
a scalpel blade, and xylocaine (4%)was applied to cut surfaces for local
anesthesia. A hole (approximately 1.0 mm in diameter) was drilled 1.0
mm caudal to bregma and 1.5 mm lateral to the midline for placement
of a sterilized 22-gauge stainless-steel cannula guide (Plastic Products,
Roanoke, VA) 1 mm above the lateral ventricle, 4.6 mm ventral to the
skull surface. Three additional holes were drilled for skull screws. The
guide was positioned and cemented to the skull surface and screws with
cranioplasticcement.A stylet wasinsertedinto the guideto prevent
exposure. The cut was then sutured, and 0.1 mlofan antibiotic (aqueous
suspension of sterile benzathine penicillin G and penicillin G procaine,
300,000 U/ml) was administered s.c. All surgical tools and implanted
materials (cannula guides and screws) were sterilized by soaking for at
least24hoursin Cidex.Surgerywasdoneunderasepticconditions.
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For i.c.v. injections, the stylet was removed and a 26-gaugecannula
(PlasticProducts,Roanoke,VA) whichwasconnectedby PE tubingto
a 10-gilHamiltonsyringewasinsertedinto the cannulaguide.The
length of the cannula exceeded the guide by 1.0 mm so that its tip was
in the lateral ventricle. The tubing was filled with the solution to be
tested. The cannula was left in place for at least 30 sec followingthe
injection to prevent efflux of the injected solutions. After removal of
the cannula, the stylet was replacet To verify patency of the i.c.v.
cannula during the course of the experiment, angiotensin (50 @igin 3
@l)was administered through the i.c.v. cannula and the onset (<60 see)
and duration (>30 see) of drinking were recorded.
Drugs. All solutionswerepreparedfreshly on the day they were
used. CRF and the CRF antagonist, a helical CRF@1 (generously
suppliedby Dr. Jean Rivier of The Peptide Biology Laboratory,The
Salk Institute, San Diego, CA), as well as chlordiazepoxide HC1 (Hoff
mann-La Roche Inc., Nutley, NJ) were dissolved in sterile 0.9% saline
solution. Flumazenil (kindly supplied by Hoffmann-La Roche Inc.) was
suspended in a vehicle consisting of sterile distilled water to which
Tween 80 (2 drops/1O ml) was added. DMCM (R.B.I., Natick, MA)
was dissolved in an acidified (HC1) saline solution. All drugs were
administered i.c.v. in a volume of 3 @l(CRY, DMCM) or 5 @l(a helical
CRF@1,chlordiazepoxideand flumazenil).
Behavioral training. Rats were trained to press the right lever
with each response producing food reinforcement (FR 1 schedule). The
experimental session was initiated by the illumination of a white
houselight. Initially, the white and green lights above the right lever
wereon;3 minlater,thesewereturnedoffandaredlightsignalingthe
initiation of the second component of the schedule was turned on.
Thesetwoschedulecomponentsalternatedevery3rain,andthesession
lasted30mm. With continuedtraining the FR responserequirement
wasprogressivelyincreaseduntil 20 leverresponseswererequiredfor
each foodpellet (FR 20). After about 25 sessions, responserates were
stable and comparable in both schedule components and ranged from
0.94to 1.88responses/sec.At this time, electricshockwasintroduced
into the second component of the schedule such that the first response
of each FR 20 resulted in the delivery of a 0.5-msec constant current
scrambledshockto the grid floor of the chamber.The intensity of the
shock used varied between individual rats (range: 0.05-0.4 mA) and
waschosenon thebasisof its ability to decreasethe rateof responding
in the second (punished) component by 10% to 15% (mean: 13.8 Â±
2.9%), i.e., 85% to 90% of nonpunishment response rates. Shock levels
wereneveradjusteduringperiodsofdrugadministration.Theexper
imental sessions were run once daily, 6 days a week (except on Sunday)
between 10:00 A.M. and 2:00 P.M.
Behavioral testing. When response rates appeared to be stable
(Le., about 10 sessions after the introduction of electric shock), as
judged by their variation of less than 10% over three consecutive
sessions, rats were prepared with i.c.v. cannulas for peptide and drug
administration. After a recovery period of 1 week, rats were retrained
in the punishment procedure. When stable base lines of responding
wereobtained,similartothoseobtainedbeforesurgery(i.e.,afterabout
16 sessions), behavioral testing began. Either CRF (0.1, 0.3, 1.0, 3.0,
5.6ag), DMCM (3, 10,30, 56, 100 @g)or saline(3 @cl)wasadministered
i.c.v.overa 30-secperiod,5 mmbeforethe startof the session.The
efficacy of various shock intensities as punishment was determined in
sessionsin whichthe shockintensity usedin the secondcomponentof
the schedule was increased (i.e., changes cf 0.1, 0.2,0.3, 0.4, 0.5 and 0.6
mA) and varied between 0d5 and 1.0 mA. Only one intensity of shock
wasused in a single session. Rats wereusuallytested twice a weekand
retrained on the other 4 days. Drug doses and shock intensity increases
werestudiedin a mixedsequencethat differedbetweensubjects.
For pharmacologic antagonism experiments, either chlordiazepoxide
(10@ flumazenil (10 ag), a helical CRFg@i(50 @@g)or vehicle (5 zl)
was administered5 mm before CRF or DMCM. In sessions designed
to investigate the effects of these antagonists on the punishing efficacy
of differentshockintensities, the antagonistswereadministered5 mm
before the start of the session.
Histology. At the endof the experiment,neutral reddye(5 @l)was
injected through the i.c.v. cannula and the rats were sacrificed by i.p.
injection of 150 mg/kg pentobarbital. The brains were removed and
sectionedfor visualizationof the dyein the ventricularsystem.
Data analysis. Data were obtained as the mean number of lever
responses per second (response rate) during the nonpunishment and
punishment components of the schedule. Drug and shock effects on
response rates were expressed as the percentage of the rates determined
during the non-drug training sessions conducted on the days before the
test sessions (% control response rate). In addition, individual suppres
sion ratio values were calculated for each drug dose or shock intensity.
Suppression ratio was defined as the ratio of response rate in the
punishment component and the sum of the response rates in both
components. This ratio typically takes values between 0, indicating a
selectiveand completesuppressionof punishedrespondingcompared
with nonpunishedresponding,and0.5,indicatingthat thenonpunished
and punished responding are equally affected.
The dose- or intensity-effect curves for the % control response rates
were analyzed by a two-way ANOVA, with schedule component as
within-subject factor 1 (two levels: nonpunished and punished respond
ing) and drug dose or shock intensity as within-subject factor 2 (six or
seven levels, respectively). The dose- or intensity-effect curves for the
suppression ratios were analyzed by one-way ANOVA, with drug dose
or shock intensity as within-subject factor (six or seven levels, respec
tively). The pharmacologicantagonismeffects on nonpunishedre
spondingandpunishedrespondingwereanalyzedseparatelyby a two
wayANOVA,with pretreatmentas within-subjectfactor1 (fourlevels)
andtreatmentas within-subjectfactor2 (fourlevels).Furtheranalyses
weremadebyDuncan'snewmultiplerangetest to determinethe source
of detected significance in the ANOVAs. The criterion of significance
was set at P < .05.
Results
Proconflict effects of CRF, DMCM and shock. Control
rates of nonpunished responding and punished responding
ranged from 0.95 to 2.16 (mean: 1.58 Â±0.12) and from 0.88 to
1.80 (mean: 1.33 Â± 0.08) responses per second, respectively.
Figure 1 shows representative data from sequential sessions for
one subject. Rates of responding in the two components of the
schedule varied little from one session to the next. With i.c.v.
administration of either CRF or DMCM, or with an increase
in the intensity of electric shock, rates of responding were
decreased, with those decreases generally greater in the punish
ment component (proconflict effect). At low to intermediate
doses the decreases were selective to the punishment compo
nent (e.g., 0.1 and 0.3 @igCRF; 3.0 and 10.0 @gDMCM; 0.2 mA
shock). Performances recovered to base line during sessions
immediately following those in which the effects of drugs or
changes in intensity of shock were assessed.Neither repeated
administration of the drugs (no more than twice weekly) nor
the order of treatments appeared to alter the reliability of
results obtained under this schedule.
The selective aspects ofthe effects ofthese drugs and changes
in shock intensity can be better observed in the dose-effect, or
intensity-effect functions (figs. 2 and 3). CRF, delivered i.c.v.,
produced a dose-related decreasein rates of both nonpunished
and punished responding. However, rates of punished respond
ing were affected at doseslower than those necessaryto de
crease nonpunished responding (fig. 2A, compare open and
filled squares). In particular, the 0.1- to 1.0-pg doses produced
selective proconflict effects, whereas higher doses (3.0, 5.6 jzg)
decreased both punished and nonpunished responding more
similarly. Thus, the CRF dose-effect curve for effects on pun
ished responding was shifted to the left of that for effects on
nonpunished responding (F1,11= 68; P < .001). The selective
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Fig. 1.Effectsof CRF,DMCMandshockonratesof nonpunished(open
symbols)and punished(filledsymbols)respondingin a representative
subject.Theabscissaeindicatethenumberof successivesessions.The
ordinates indicate mean response rates expressed as number of lever
pressespersecond.Eachpointrepresentstheresponseratedetermined
ineathcomponentof themultiplescheduleduringthatparticularsession.
The numbersundercertainpoints indicatea drug dose (micrograms,
i.c.v.) or increase in shock intensity (milliamperes)that was used in the
testsession.Noteselectivesuppressionof punishedrespondingelicited
byCRF(0.1â€”1.0 @g)andDMCM(3â€”30gig).
aspectsof the effects can also be seen in the suppression-ratio
values (fig. 2B, squares) which show a dose-related decrease up
to a dose of 1 @g,with a reversal of this trend at the higher
doses.
DMCM also decreased response rates in both components of
the schedule (fig. 2A, circles). Rates of responding in the
punishment component were selectively decreased (fig. 2A,
compare open and filled circles), particularly at the lower doses
(10-30 ag). Similar to CRF, the DMCM dose-effectcurve for
effectson punishedrespondingwas shifted to the left of that
for effectson nonpunishedresponding(F1,9= 39; P < .001).
The selective aspects ofthe effects of DMCM are also exhibited
as a decrease in the suppression-ratio values (fig. 2B, circles).
















Vshlcls.1 1 10 100
DRUG DOSE (Mg)
Fig. 2. Dose-responsecurvesfor the pr000nfhcteffectsof CRF and
DMCMonpunishedbehavior.TheabscissaeIrdcatethedose(micro
grams,i.c.v.;kg scale).PanelA: Shownaredose-responsecurvesfor
effects of CRF (squares)and DMCM(circles)on nonpunished(open
symbols)and punished(filledsymbols)responding.Theordinatesk@dl
catethe responseratesexpressedas a percentageof the ratesdeter
minedduhng the nondrugcontrol sessbn 1 day before the test sessbns.
Eachpointis themeanof 10to 12rats.VerticalNnesindicateÂ±1S.E.M.
Pointsat vehiclerepresentsessionswhen vehiclewas administered.
Two-wayANOVAon the valuesin panelA revealedsignfficantmain
effectsof schedulecomponent(CRF:F1,11= 68.3,P< .001; DMCM:F1.9
= 39.1, P < .001) and drug dose (CRF: F5,M 9.7, P < .001; DMCM:
F5@= 59.4, P < .001) as well as a significantschedulecomponentx
drugdoseInteractioneffect(CRF:F5,@= 9.7, P < .001; DMCM:F5.@=
7.2; P < .001).Asterisksindicatethatvaluesforpunishedresponding
are significantly(at leastP < .05; Duncan's)lowerthancorresponding
values for nonpunishedresponding. PanelB: Shown are dose-response




effectof drugdose(CRF:F5@= 4.72,P < .01; DMCM:FL@= 6.7,P<
.001).Asterisks indicate a significant(at least P < .05; Duncan's) differ
encefrom the vehiclevalue.Note that both drugsare morepotent in
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120 A rates of responding in the punishment component compared
with the alternate component, resulting in a statistically sig
@ 100 A nificant shift to the left in the intensity-effect curve for effects
on punished responding compared with that for effects on
@ nonpunished responding (F1,7= 55, P < .001). The suppression
@ 80 ratio values (fig. 3B) show a monotonic decrease with increasing
values for the change in the intensity of electric shock.
@ 60 Antagonism of CRF, DMCM and shock. Figure 4 shows
@ the effects of various pretreatments on the behavioral effects
-I
0 producedby CRF, DMCM and shock-intensitychanges.Pre@ 40
@ treatment with two i.c.v. vehicle injections (left-most open bar)8 20 didnotappreciablyaffectratesofrespondingineitherthe
@t nonpunishment component (fig. 4A) or the punishment com
ponent (fig. 4B). The anxiolytic benzodiazepine, chlordiazepox
0 * ide (10 @Lg),when administeredalone i.c.v. (left-most bar with
, I horizontal stripes), did not alter either rates of nonpunished0 .1 .3 1 (fig. 4A) or punished responding (fig. 4B). Pretreatments with
A SHOCKINTENSITY(mA) either the benzodiazepine antagonist, flumazenil (10 @g;left
most filled bar), or the CRF antagonist, a helical CRF9@1 (50
;Lg; left-most bar with vertical stripes), were similarly inactive.
0.5 B The 10-gig dose of chlordiazepoxide significantly attenuated
the response rate suppressing effects of equally effective doses
. 4 of both CRF and DMCM (bars with horizontal stripes above
@ 0 4 appropriate drugs). This antagonism was obtained in both
components of the schedule. While the effects of these drugs
@ were attenuated, rates of responding were not restored com
z 0.3 pletelyto controllevels.Chlordiazepoxidepretreatmentsimi
Q@ larly diminished the effects of a change in shock intensity that
was aseffective as CRF and DMCM (fig. 4, right-most bar withUI 0.2
0. horizontal stripes).
0.@ Pretreatment with the CRF antagonist, a helical CRF941(50
U) 0.1 @tg), almost completely prevented the effects of CRF on re
* sponding in both components of the schedule (fig. 4, filled bar
over CRF). Similarly, the suppression of responding by electric
0.0 shock was significantly attenuated by the CRF antagonist,
0 .1 .3 1 although to a lesser extent than was suppression by CRF (fig.
4, right-most filled bar). In contrast, the suppressant effects of
L@SHOCK INTENSITY (mA) DMCM were not significantly attenuated by pretreatment with
FIg.3. Intensity-effectcurvesfor thesuppressanteffectsof electricfoot- a helical CRF9@1(fig. 4, filled bar over DMCM).
shock on punishedbehavior.The abscissaeindicatethe changein The benzodiazepine antagonist, flumazenil (10 pg), produced
electricshockintensityin milliamperes(logscale).PanelA: Shownare
intensity-responsecurvesfor effectson nonpunished(opensymbols) viftually a complete antagonism of the effects of CRF and
and punished(filled symbols)responserate. The ordinate indicates DMCM on rates of nonpunished and punished responding (fig.
responserateexpressedasa percentageof theratesdeterminedduring 4,bars with vertical stripes). In contrast, the effects of a change
the trainingsession1 day beforethe test session.Eachpoint is the in the intensity of electric shock were unaffected by flumazenil
meanof 8 rats.VerticallinesrepresentÂ±1 S.E.M.Two-wayANOVAon
thesevaluesrevealedsignificanteffectsof the mainfactors,schedule pretreatment.
component(F1.7= 54.9,P < .001)andshockintensity(F6,42= 32.8,P<
.001), as well as a significantinteraction effect (F6,42= 5.3, P < .001). Discussion
Asterisksindicatethat valuesfor punishedrespondingare significantly
(at leastP < .05;Duncan's)lowerthancorrespondingvaluesfornon
punishedresponding.PanelB: Intensity-responsecurvefor the effects
of shockon the suppressionratios.One-wayANOVAon thesevalues
yieldeda significanteffectof shock intensity(F6,@= 21.3, P < .001).
Asterisks indicate a significant (at least P < .05; Duncan's) difference
fromthe pointzerovalue.
The results demonstrate that i.c.v. administration of CRF
and DMCM have identical effects on food-reinforced respond
ing generated by the multiple schedule used in the present
study; i.e., CRF and DMCM decreased nonpunished responding
and responding that was punished by a relatively low-intensity
shock. The proconflict effect of each of these drugs was mdi
cated by the finding that punished responding was more sen
sitive to the effects of certain doses of the drugs than was
nonpunished responding. Increasing the shock intensity in the
punishment component mimicked the drug effects, further
indicating a proconflict effect of these drugs. These results are
consistent with other studies that demonstrate suppressant
effects of CRF and benzodiazepine inverse agonists on food
reinforced responding (Prado de Carvalho et aL, 1983;Quintero
Increases for a single session in the intensity of shock deliv
ered in the punishment component produced decreasesin rates
of responding in the two components (fig. 3A). Changes in
intensity as small as 0.1 mA were effective in decreasing rates
of responding. These decreases in rates of responding were
greater in the punishment component, but also occurred in the
alternate component in which shocks were never delivered.
Smaller increases in shock intensity were effective in decreasing
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indicatingthat the effectsofthe benzodiazepineinverseagonist
DMCM are not mediated through endogenous CRF release.
Finally, the finding that the CRF antagonist attenuates the
effectsofelectricshocksuggestshat theshock-mediatedpun
ishment process may be, at least in part, mediated by CRF
release.
Previous studies of the effects of CRF on punished behavior
failed to show selective proconflict effects of any dose of CRF
(Britton et at., 1985, 1988; Britton and Koob, 1986; Barrett et
aL, 1989). In these studies the CRF dose-response curves for
suppression of punished responding and suppression of non
punished responding were almost superimposable.This general
reduction in operant responding was interpreted to be related
to the ability of CRF to suppressappetitive motivation (Levine
et aL, 1983). The subjects of these studies were either rats
(Britton et at., 1985, 1988; Britton and Koob, 1986) or pigeons
(Barrett et al., 1989), and either random-interval (Britton et
at., 1985,1988;Britton and Koob, 1986) or fixed-ratio (Barrett
et ci., 1989) schedules were used. One major difference between
the present and previous studies involves the intensity of the
punishing stimulus. In the previous studies, shock intensities
were used that decreased the rate of responding to 3% to 15%
of the rate of nonpunished responding. This is in contrast to
the present study, which used a shock intensity that decreased
the rate of responding to only 85% to 90% of the nonpunish
ment rate. Like CRF, the benzodiazepine inverse agonists, @-
CCE and noreleagnine, have been shown to have selective
proconflict effects that are determined by the intensity of the
shock used as a punisher (Shekhar et at., 1989; Takada et aL,
1992). Taken together, these studies suggest that there is an
optimal range of shock intensities that can be used to demon
strate selective proconflict effects. It is likely that if shock
intensity is too low, selective proconflict effects will not be
observed. Alternatively, if shock intensity is too high, a ceiling
effect may be reached whereby drug pretreatment cannot de
crease responding further. The proconflict effects of both CRF
and DMCM are also dependent on drug dose such that only
intermediate doses have selective effects. This was also ob
served with fi-CCE (Takada et aL, 1992). Although it is possible
that the differences in dose- or intensity-effect curves for effects
on punished and nonpunished responding observed in the pres
ent studywere due to differencesin responserates in the two
components, this is unlikely because the response rates were
selected to be relatively similar in both components. Addi
tionally, the predictedrate-dependenteffectwouldbe opposite
to the results obtained, i.e., higher rates of responding in the
nonpunished component would be more sensitive to suppres
sion.
In spite of the finding that CRF exhibited more selectivity
in this study than in previous studies using other schedules or
higher shock intensities, it may be surprising that a greater
separation between dose-responsecurves for effects on pun
ished and nonpunished responding wasnot observed.The small
degree of selectivity was not specific to CRF but was also
observed with the benzodiazepine inverse agonists, DMCM
(present study) and @9-CCE(Takada et at., 1992), and may be a
function of the multiple schedule used to assessproconflict
effects. When rats were tested at a higher shock intensity in
the present study, response rates in both components of the
multiple schedule decreased and the degree of selectivity of
suppression was comparable with that observed with CRF or
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TREATMENT
FIg.4.Antagonismofthe effectsofCRF,DMCMandshock.Theordinate
representsthe responserateexpressedas a percentageof the rate
determinedon trainingsessions1 day beforethe test. The abscissae
indicatevehicle(3 al),CRF(1.0 @zg),DMCM(56 gig)or shock(0.4 mA
increase) treatment dunng the test session. Rats were pretreated (10
mmbeforetest session)witheithervehicle(5 @l;openbars),chlordiaze
poxide(CDP;10 ,@g;horizontalstripedbars),a helicalCRFÃ˜..@Il(50 ,@g;
closedbars)or flumazenil(10 @g;verticalstripedbars).Eachbar is the
meanof 6 rats and verticallinesindicateÂ±1 S.E.M.PanelsA and B
show effectson nonpunishedand punishedresponding,respectively.
Two-wayANOVAonthevaluesinpanelsA andB revealedsignificant
treatment(A: F3,15= 36.5, P < .001; B: F315= 60.5, P < .001)and
pretreatment(A:F315= 58.3,P < .001; B: F3,5= 23.2,P < .001)main
effects,aswellasasignificanttreatmentx pretreatmentinteraction(A:
F9@= 17.0, P < .001; B: F945= 11.8, P < .001). Asterisksindicatea
significant(atleastP< .05;Duncan's)differencefromthecorresponding
vehiclepretreatmentvalues.
et at., 1985; Britton et al., 1985, 1988; Britton and Koob, 1986;
Koob et aL, 1986;Barrett et al., 1989;Zhang and Barrett, 1990)
and extend these studies by demonstrating that selective effects
of CRFandDMCMon punishedresponding(proconflictef
fects)aredeterminedbytheintensityofthepunishingstimulus.
The finding that both a benzodiazepine agonist and antagonist
prevent the effects ofDMCM and CRF implies a pharmacologic
interaction between CRF and endogenous benzodiazepine
receptor systems. Furthermore, the CRF antagonist, a helical
CRF941, did not antagonize the behavioral effects of DMCM,
B Punished Responding
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studies of intensity of the punishing stimulus have found a
greater selective suppression of response rates by shock as
intensity was increased (Dinsmoor, 1952; Brethower and Rey
nolds, 1962; Katz and Goldberg, 1986). One explanation for
this discrepency is that the repeated exposure to the high shock
intensity that occurs during behavioral training can result in
enhanced discriminative control by the stimuli associated with
the schedule components. The high shock intensities used in
the present study were relatively novel, because they were not
presented on a daily basis. It has been demonstrated previously
that high-intensity or novel aversive stimuli have generalized
behavioral suppressant effects (Azrin and Holz, 1966).
The effectsof CRF on food-reinforcedrespondingwerelikely
mediated by an interaction with specific CRF binding sites
becausethe dosesof CRF that were effective were comparable
with those that elicit adrenocorticotropin hormone release
(Vale et a!., 1981) or mimic autonomic responses to stress
(Brown et a!., 1982; Fisher et at., 1982). More importantly
however, these behavioral effects of CRF are prevented by
pretreatment with a dose of a CRF antagonist that has been
demonstrated to prevent other effects of CRF (Rivier et aL,
1982; Kahn et al., 1988; Lenz et at., 1988) or stress-elicited
effects (Brown et al., 1986; Lenz et aL, 1988; Valentino and
Wehby, 1988). This finding confirms previous studies (Britton
et aL, 1986; Barrett et al., 1989). Interestingly, the DMCM
induced effects on nonpunished and punished responding were
not blocked by the CRF antagonist. Although higher doses of
a helical CRF9@1may be necessary to antagonize DMCM, the
dose used was sufficient to almost completely antagonize an
equally effective dose of CRF. This suggests that the effects of
benzodiazepine inverse agonists on punished responding are
not mediated via endogenous CRF release. Furthermore, while
the CRF antagonist did not alter the suppressive effects of low
intensity shock on response rate, it did attenuate the behavioral
suppression elicited by the higher intensity shock, suggesting
that part of the punishing effects of shock are due to endoge
nous CRF release. In two earlier studies (Britton et aL, 1986;
Barrett et aL, 1989) a helical CRF941had no effect on response
suppression elicited by high-intensity shock in a conflict pro
cedure.However, in contrast to previous studies, the high shock
intensity used in the present study was novel. This additional
characteristic of shock, i.e., novel us. nonnovel, may be an
important determinant in sensitivity to a CRF antagonist and
suggeststhat endogenousCRF systems are in effect in behav
ioral responsesto novel aversive stimuli.
As expected,both the benzodiazepine receptor agonist, chlor
diazepoxide, and the benzodiazepine receptor antagonist, flu
mazenil, attenuated the suppressive effects of the benzodiaze
pine inverse agonist, DMCM, indicating a central benzodiaze
pine receptor-mediated mechanism of action for this DMCM
effect. As previouslyreported in a variety of animal tests of
anxiety, including punishment procedures (Britton et al., 1985,
1988; Lee et al., 1987; Dunn and File, 1987; Yang et at., 1990;
Zhang and Barrett, 1990), the anxiolytic chiordiazepoxide also
attenuated the suppressive effects of CRF and high-intensity
shock. It is likely that higher i.c.v. doses of chlordiazepoxide
are needed to completely reverse the suppressant effects of
these stimuli. The reversal of CRF by chiordiazepoxide has
beeninterpretedasa physiologicantagonism,i.e.,an anxiolytic
opposing the effects of an anxiogenic, rather than a pharma
cologicinteractionat the benzodiazepine/GABAreceptorcom
plex (Dunn and File, 1987; File, 1990). However, this explana
tion does not seemto be valid, since 1) the clinically effective
anxiolytic buspirone, which does not interact with the benzo
diazepine/GABA receptor complex, failed to attenuate the ef
fects of CRF (Zhang and Barrett, 1990; Lazosky and Britton,
1991), and 2) the benzodiazepine receptor antagonist, fluma
zenil, was an effective antagonist of CRF effects in punishment
procedures (Britton et al., 1988;this study). The latter finding
clearly points to a pharmacologic antagonism of the CRF
effects, which may occur either at the CRF-receptor level (i.e.,
flumazenil servesas a CRF-receptor antagonist) or at the level
of thebenzodiazepiner ceptor(i.e.,CRFitselfor an endoge
nous ligand releasedby CRF acting asa benzodiazepine inverse
agonist). Thus far, there is no direct evidence available either
from ligand-binding studies that CRF has affinity for benzo
diazepine receptors or that benzodiazepine ligands bind to CRF
receptors, or from neurochemical studies that exogenously ad
ministered CRF induces the releaseof endogenousbenzodiaze
pine inverse-agonistligands.
Recently, a brain peptide, DBI, was isolated, purified, se
quenced, measured and cloned, which seems to fulfill many of
the requirements for an endogenous inverse-agonist ligand for
the benzodiazepine receptor (see for review: Costa and Guidotti,
1991). When given i.c.v., DBI and one of its natural processing
products, i.e., octadecaneuropeptide, were found to elicit pro
conflict effects that were antagonized by flumazenil pretreat
ment (Costa and Guidotti, 1991). Therefore, it is tempting to
speculate that exogenous CRF may produce its â€œ¿anxiogenicâ€•
effects by releasing an endogenous inverse-agonist ligand for
benzodiazepine receptors (i.e., DBI or its fragment, octadeca
neuropeptide), which in turn can be blocked by flumazenil.
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